- Published at
- by rttnews.com
mixed
mixed
Biotech Stocks Facing FDA Decision In August 2025
The FDA decision on PharmaTher Holdings' resubmitted Abbreviated New Drug Application for racemic ketamine KETARX is due on August 9, 2025..
News for PharmaTher Holdings Ltd. (PHRM.CN)
- Published at
- by gurufocus.com
positivepositivePharmaTher Applauds FDA's New Commissioner's National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and Nat
PharmaTher Holdings (OTCQB: PHRRF) supports FDA's new CNPV program, aiming to expedite ketamine therapies. The company targets an FDA approval date of A- Published at
- by gurufocus.com
neutralneutralPharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. ( PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company fo- Published at
- by gurufocus.com
neutralneutralPharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization
KetaVaultâ„¢ to Provide Partners Unprecedented Access to PharmaTher's Extensive Regulatory, Manufacturing, and Clinical Ketamine Data, Aiming to Expedite New T- Published at
- by gurufocus.com
neutralneutralPharmaTher Receives US FDA Approval Goal Date for Ketamine
The Assigned FDA Approval Goal Date is June 4, 2025 TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the ”Company” or ”PharmaTher- Published at
- by gurufocus.com
neutralneutralPharmaTher Provides Update on FDA New Drug Application for Ketamine
PharmaTher expects to submit the MINOR AMENDMENT to the CRL by end-February 2025 and expects a new approval date for a Q2-2025 FDA approval of ketamine TORONT- Published at
- by gurufocus.com
neutralneutralPharmaTher CEO Issues Letter to Shareholders
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the ”Company” or ”PharmaTher”) ( PHRRF) (CSE: PHRM), a specialty pharmaceutical c- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
neutralneutralPharmaTher Announces Update on FDA New Drug Application for Ketamine
FDA provided preliminary responses to questions contained in the clarification only post-CRL meeting scheduled for December 2, 2024 PharmaTher has decided to- Published at
- by investing.com
positivepositivePharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases By In
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases- Published at
- by financialpost.com
neutralneutralPharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application
TORONTO, Oct. 23, 2024 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company,…- Published at
- by investing.com
mixedmixedPharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases By Investing.com
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases- Published at
- by financialpost.com
mixedmixedPharmaTher's Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company,…- Published at
- by investing.com
positivepositivePharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine By Investing.com
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine- Published at
- by financialpost.com
positivepositivePharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical…- Published at
- by financialpost.com
mixedmixedPharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical…- Published at
- by benzinga.com
mixedmixedPsyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs
Psychedelics policy action took center stage this week.- Published at
- by benzinga.com
mixedmixedPsyched: Third Michigan City Decriminalizes Psychedelics, MindMed Reports $133M Cash Position, Real Brands To Enter The Space
The psychedelics legislative landscape continues to move forward with Hazel Park, Michigan enacting decriminalization measures for naturally-produced psychedeli...- Published at
- by benzinga.com
mixedmixedPsyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS - ATA (ATAI), Cybin Inc. Common Shares (CYBN), FIELD TRIP HEALTH CM (FTRP)
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:- Published at
- by investorideas.com
mixedmixedPsilocybin Sector Snapshot; Stocks Discussed (OTC: $LRSV) (OTCQB: $SHRMF) (OTCQB: $MMEDF) (OTC: $RVVTF)
Point Roberts, WA and Delta, BC - February 24, 2021 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource on health and wellness stoc...